Overall, the trial provided landmark evidence supporting dual checkpoint inhibition in advanced NSCLC and expanded understanding of immunotherapy beyond PD-L1 high patients, but its complex design, heterogeneous outcomes, and safety considerations highlight the need for careful patient selection and further studies to optimize therapeutic strategies. Here, CD274 is linked to non-small cell lung carcinoma.